TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Adjuvant osimertinib delivers long-term survival benefit in EGFR-mutated NSCLC

An exploratory eight-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB-IIIA non-small cell lung cancer (NSCLC).

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Sep 13, 2026-

Adjuvant Osimertinib Demonstrates Sustained OS Benefit in Resected EGFR-Mutated NSCLC

Presented by Roy S. Herbst, MD, PhD, an exploratory analysis of the global phase III ADAURA trial reveals sustained overall survival benefit—over the longest follow-up to date—in resected EGFR-mutated NSCLC. The post Adjuvant Osimertinib Demonstrates Sustained OS Benefit in Resected EGFR-Mutated NSCLC appeared first on ILCN.org (ILCN/WCLC).

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting